Clinicopathological features associated with CD44 and CD63 expression in breast cancer
Descripción del Articulo
Background: CD44 is a cell-surface transmembrane glycoprotein that participates in the regulation of many cellular processes, including cell division, adhesion, migration and stem-like characteristics. CD63 is involved in the exocytosis process. Objective: To evaluate the relationship between CD44 a...
| Autores: | , , , , , , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2024 |
| Institución: | Instituto Nacional de Enfermedades Neoplásicas |
| Repositorio: | INEN-Institucional |
| Lenguaje: | inglés |
| OAI Identifier: | oai:repositorio.inen.sld.pe:20.500.14703/377 |
| Enlace del recurso: | https: //doi.org/10.3332/ecancer.2024.1779 https://hdl.handle.net/20.500.14703/377 |
| Nivel de acceso: | acceso abierto |
| Materia: | breast cancer CD44 CD63 tumor-infiltrating lymphocytes https://purl.org/pe-repo/ocde/ford#3.02.21 |
| id |
INEN_e753b85421a9f22aa813dad4c5e2fce5 |
|---|---|
| oai_identifier_str |
oai:repositorio.inen.sld.pe:20.500.14703/377 |
| network_acronym_str |
INEN |
| network_name_str |
INEN-Institucional |
| repository_id_str |
. |
| spelling |
PublicationCastaneda, CACastillo, MSanchez, JBernabe, LTello, KSuarez, NAlatrista, RQuiroz-Gil, XGranda-Oblitas, AEnciso, JEnciso, NGomez, HL2025-05-05T17:29:35Z2025-05-05T17:29:35Z2024https: //doi.org/10.3332/ecancer.2024.1779https://hdl.handle.net/20.500.14703/377ecancermedicalscienceBackground: CD44 is a cell-surface transmembrane glycoprotein that participates in the regulation of many cellular processes, including cell division, adhesion, migration and stem-like characteristics. CD63 is involved in the exocytosis process. Objective: To evaluate the relationship between CD44 and CD63 expression and clinicopathological features, including tumor-infiltrating lymphocytes (TILs), phosphoinositide 3-kinase (PIK3CA) mutation and survival. Methodology: CD44 and CD63 were stained in samples from 101 breast cancer cases from Peruvian women. Results: Median age was 52 years, most were most were grade-3 (68%), estrogen receptor (ER)+ (64%) and stage II-III (92%). Median ki67 was 30%, median stromal TIL was 30% and PIK3CA mutation was found in 49%. Longer survival was associated with earlier stages (p = 0.016), lower ki67 (p = 0.023), ER+ (p = 0.034), luminal phenotype (p = 0.029) and recurrence (p < 0.001). CD44 was classified as high cell density staining in 57% and high intensity in 55%. High CD44 density was associated with younger age (p = 0.043), triple-negative phenotype (p = 0.035) and shorter survival (p = 0.005). High CD44 expression was associated with short survival (p = 0.005). High CD63 cell density was found in 56% of cases and was associated with ER-positive (p = 0.045), low TIL levels (p = 0.007), Luminal-A (p = 0.015) and low CD44 intensity (p = 0.032). Conclusion: CD44 expression was associated with aggressive features and low CD63 density staining.his work was supported by CONCYTEC (contract 007-2016-FONDECYT) and Universidad Cientifica del Sur.application/pdfengecancer Global FoundationUKinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/4.0/breast cancerCD44CD63tumor-infiltrating lymphocyteshttps://purl.org/pe-repo/ocde/ford#3.02.21Clinicopathological features associated with CD44 and CD63 expression in breast cancerinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:INEN-Institucionalinstname:Instituto Nacional de Enfermedades Neoplásicasinstacron:INENORIGINALcan-18-1779.pdfapplication/pdf481692https://repositorio.inen.sld.pe/backend/api/core/bitstreams/fa736027-d8e5-43d2-bfcb-0b5763f29945/downloada831fd7286b6614df5e31f37f8c94e61MD51trueAnonymousREADTEXTcan-18-1779.pdf.txtWritten by FormatFilter org.dspace.app.mediafilter.TikaTextExtractionFilter on 2025-08-22T08:02:33Z (GMT).Extracted texttext/plain42345https://repositorio.inen.sld.pe/backend/api/core/bitstreams/b264d97a-86d3-470c-85a5-a65d477a7a0b/downloada155244cd2ae7c59a183c7dd865df9a3MD52falseAnonymousREADTHUMBNAILcan-18-1779.pdf.jpgWritten by FormatFilter org.dspace.app.mediafilter.PDFBoxThumbnail on 2025-08-22T08:02:34Z (GMT).Generated Thumbnailimage/jpeg38072https://repositorio.inen.sld.pe/backend/api/core/bitstreams/5cd5e129-9fbf-49d2-8a12-f72c02a8955e/download2bf65bc094dc120333ade4ab4040c2ccMD53falseAnonymousREAD20.500.14703/377oai:repositorio.inen.sld.pe:20.500.14703/3772026-02-16T20:31:05.100Zhttps://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessopen.accesshttps://repositorio.inen.sld.peRepositorio del Instituto Nacional de Enfermedades Neoplásicasrepositorio@inen.sld.pe |
| dc.title.none.fl_str_mv |
Clinicopathological features associated with CD44 and CD63 expression in breast cancer |
| title |
Clinicopathological features associated with CD44 and CD63 expression in breast cancer |
| spellingShingle |
Clinicopathological features associated with CD44 and CD63 expression in breast cancer Castaneda, CA breast cancer CD44 CD63 tumor-infiltrating lymphocytes https://purl.org/pe-repo/ocde/ford#3.02.21 |
| title_short |
Clinicopathological features associated with CD44 and CD63 expression in breast cancer |
| title_full |
Clinicopathological features associated with CD44 and CD63 expression in breast cancer |
| title_fullStr |
Clinicopathological features associated with CD44 and CD63 expression in breast cancer |
| title_full_unstemmed |
Clinicopathological features associated with CD44 and CD63 expression in breast cancer |
| title_sort |
Clinicopathological features associated with CD44 and CD63 expression in breast cancer |
| author |
Castaneda, CA |
| author_facet |
Castaneda, CA Castillo, M Sanchez, J Bernabe, L Tello, K Suarez, N Alatrista, R Quiroz-Gil, X Granda-Oblitas, A Enciso, J Enciso, N Gomez, HL |
| author_role |
author |
| author2 |
Castillo, M Sanchez, J Bernabe, L Tello, K Suarez, N Alatrista, R Quiroz-Gil, X Granda-Oblitas, A Enciso, J Enciso, N Gomez, HL |
| author2_role |
author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Castaneda, CA Castillo, M Sanchez, J Bernabe, L Tello, K Suarez, N Alatrista, R Quiroz-Gil, X Granda-Oblitas, A Enciso, J Enciso, N Gomez, HL |
| dc.subject.none.fl_str_mv |
breast cancer CD44 CD63 tumor-infiltrating lymphocytes |
| topic |
breast cancer CD44 CD63 tumor-infiltrating lymphocytes https://purl.org/pe-repo/ocde/ford#3.02.21 |
| dc.subject.ocde.none.fl_str_mv |
https://purl.org/pe-repo/ocde/ford#3.02.21 |
| description |
Background: CD44 is a cell-surface transmembrane glycoprotein that participates in the regulation of many cellular processes, including cell division, adhesion, migration and stem-like characteristics. CD63 is involved in the exocytosis process. Objective: To evaluate the relationship between CD44 and CD63 expression and clinicopathological features, including tumor-infiltrating lymphocytes (TILs), phosphoinositide 3-kinase (PIK3CA) mutation and survival. Methodology: CD44 and CD63 were stained in samples from 101 breast cancer cases from Peruvian women. Results: Median age was 52 years, most were most were grade-3 (68%), estrogen receptor (ER)+ (64%) and stage II-III (92%). Median ki67 was 30%, median stromal TIL was 30% and PIK3CA mutation was found in 49%. Longer survival was associated with earlier stages (p = 0.016), lower ki67 (p = 0.023), ER+ (p = 0.034), luminal phenotype (p = 0.029) and recurrence (p < 0.001). CD44 was classified as high cell density staining in 57% and high intensity in 55%. High CD44 density was associated with younger age (p = 0.043), triple-negative phenotype (p = 0.035) and shorter survival (p = 0.005). High CD44 expression was associated with short survival (p = 0.005). High CD63 cell density was found in 56% of cases and was associated with ER-positive (p = 0.045), low TIL levels (p = 0.007), Luminal-A (p = 0.015) and low CD44 intensity (p = 0.032). Conclusion: CD44 expression was associated with aggressive features and low CD63 density staining. |
| publishDate |
2024 |
| dc.date.accessioned.none.fl_str_mv |
2025-05-05T17:29:35Z |
| dc.date.available.none.fl_str_mv |
2025-05-05T17:29:35Z |
| dc.date.issued.fl_str_mv |
2024 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.version.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.doi.none.fl_str_mv |
https: //doi.org/10.3332/ecancer.2024.1779 |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.14703/377 |
| dc.identifier.journal.none.fl_str_mv |
ecancermedicalscience |
| url |
https: //doi.org/10.3332/ecancer.2024.1779 https://hdl.handle.net/20.500.14703/377 |
| identifier_str_mv |
ecancermedicalscience |
| dc.language.iso.none.fl_str_mv |
eng |
| language |
eng |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.uri.none.fl_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
ecancer Global Foundation |
| dc.publisher.country.none.fl_str_mv |
UK |
| publisher.none.fl_str_mv |
ecancer Global Foundation |
| dc.source.none.fl_str_mv |
reponame:INEN-Institucional instname:Instituto Nacional de Enfermedades Neoplásicas instacron:INEN |
| instname_str |
Instituto Nacional de Enfermedades Neoplásicas |
| instacron_str |
INEN |
| institution |
INEN |
| reponame_str |
INEN-Institucional |
| collection |
INEN-Institucional |
| bitstream.url.fl_str_mv |
https://repositorio.inen.sld.pe/backend/api/core/bitstreams/fa736027-d8e5-43d2-bfcb-0b5763f29945/download https://repositorio.inen.sld.pe/backend/api/core/bitstreams/b264d97a-86d3-470c-85a5-a65d477a7a0b/download https://repositorio.inen.sld.pe/backend/api/core/bitstreams/5cd5e129-9fbf-49d2-8a12-f72c02a8955e/download |
| bitstream.checksum.fl_str_mv |
a831fd7286b6614df5e31f37f8c94e61 a155244cd2ae7c59a183c7dd865df9a3 2bf65bc094dc120333ade4ab4040c2cc |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio del Instituto Nacional de Enfermedades Neoplásicas |
| repository.mail.fl_str_mv |
repositorio@inen.sld.pe |
| _version_ |
1868438553726287872 |
| score |
12.821158 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).